摘要
目的:探讨文拉法辛合并舒必利治疗精神分裂症的疗效和安全性。方法:将68例精神分裂症患者随机分为研究组与对照组,研究组给予文拉法辛合并舒必利治疗,对照组用利培酮治疗,疗程8周,用阳性与阴性症状量表(PANSS)、简明精神病评定量表(BPRS)以及治疗中出现的症状量表(TESS)评定疗效和安全性。结果:治疗8周研究组总有效率为88.24%,对照组为67.65%,两组比较差异有统计学意义(P<0.05)。治疗后两组PANSS及BPRS评分均有明显下降(P<0.05或P<0.01),研究组下降更显著(P<0.05)。结论:文拉法辛合并舒必利治疗精神分裂症阴性与阳性症状疗效可靠,不良反应小。
Objective： To explore the efficacy and safety of venlafaxine combined with sulpiride in treatment of schizophrenia. Method： 68 schizophrenia patients were divided into two groups randomly, 34 were treated with venlafaxine combining sulpiride ,34 with risperidone. The period of observation is 8 weeks, positive and negative symptom scale（ PANSS）, brief psychiatric rating scale （BPRS） and treatment emergent symptom scale（TESS） were used to assess efficacy and safety of the two groups . Results： Effective rates of the two groups were 88.24% and 67.65% respectively （P 〈 0.05）. Total scores of PANSS and BPRS decreased signif- icantly in both groups after the treatment （P 〈 0.05 or P 〈 0.01 ）, and venlafaxine combining sulpiride group decreased more. Conclusion： Venlafaxine combining sulpiride is an effective choice in treating positive and negative symptoms of schizophrenia with mild side effects.
出处
《临床精神医学杂志》
2009年第4期263-264,共2页
Journal of Clinical Psychiatry
